Thursday, 6 July 2017

Protein Engineering Makes Rapid Strides

Does Protein Engineering or the process of developing useful proteins excite you? Then do sign up for the summer school on “Rational Approaches towards Protein Engineering & Design” (RATPED – 2017) between July 10- July 14​, ​2017. It's organized by the School of Life sciences, Crescent University. For info, visit http://bit.ly/2tg3PXU

The global protein engineering market size was valued at US$ 823.0 million in 2016 and is anticipated to grow at a CAGR of 15.9% till 2025. The market is predominantly driven by increasing preference for protein therapeutics over non protein drugs. The high preference is a consequence of positive clinical outcomes associated with these drugs.

Crescent University is home to one of the most dynamic and research-oriented Life Sciences School in the country, providing students, faculty, and staff with the opportunity to learn and perform research in a highly integrative and interactive setting.

It has over 12 active faculty research laboratories studying areas spanning biotechnology, biochemistry, microbiology, molecular biology, and genetics.

The school is dedicated to achieving excellence in graduate training and undergraduate learning. Undergraduates benefit from having world experts present the topics of their research passions in the classroom, exposing them to both the fundamental principles and the latest advancements or breakthroughs in biotechnology.

Graduate students pursue both M.Sc. and Ph.D. degrees. Our upper level curriculum offers advanced training and specialization through course work and formative research experiences.

PhD students join research teams either through our own extremely flexible graduate program in Biosciences or through a diverse array of interdisciplinary programs, such as Polymer Technology.

The school also offers many short term diploma courses well-suited for employment in corporate hospitals and industry.

Protein engineering is broadly used to circumvent weaknesses associated with drugs, and it possesses the potential to enhance affinity & efficacy of molecules for wide range applications, such as cardiac repair. The engineered molecules exhibit enhanced efficacy, reduced immunogenicity, greater safety, and improved delivery. Humulin (human insulin), the first protein therapeutic developed through recombinant DNA technology, was approved by U.S.FDA in 1982.

No comments:

Post a Comment